![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TCHH |
Gene summary for TCHH |
![]() |
Gene information | Species | Human | Gene symbol | TCHH | Gene ID | 7062 |
Gene name | trichohyalin | |
Gene Alias | THH | |
Cytomap | 1q21.3 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q07283 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7062 | TCHH | LZE4T | Human | Esophagus | ESCC | 1.48e-34 | 1.25e+00 | 0.0811 |
7062 | TCHH | LZE22T | Human | Esophagus | ESCC | 1.54e-04 | 4.15e-01 | 0.068 |
7062 | TCHH | P15T-E | Human | Esophagus | ESCC | 5.62e-30 | 7.97e-01 | 0.1149 |
7062 | TCHH | P17T-E | Human | Esophagus | ESCC | 2.68e-03 | 2.84e-01 | 0.1278 |
7062 | TCHH | P28T-E | Human | Esophagus | ESCC | 5.03e-37 | 6.36e-01 | 0.1149 |
7062 | TCHH | P36T-E | Human | Esophagus | ESCC | 1.47e-14 | 6.33e-01 | 0.1187 |
7062 | TCHH | P84T-E | Human | Esophagus | ESCC | 1.34e-04 | 2.45e-01 | 0.0933 |
7062 | TCHH | C06 | Human | Oral cavity | OSCC | 6.22e-04 | 5.36e-01 | 0.2699 |
7062 | TCHH | C08 | Human | Oral cavity | OSCC | 2.11e-24 | 5.28e-01 | 0.1919 |
7062 | TCHH | SYSMH5 | Human | Oral cavity | OSCC | 4.24e-06 | 2.61e-01 | 0.0647 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
GO:000991310 | Esophagus | ESCC | epidermal cell differentiation | 122/8552 | 202/18723 | 1.69e-05 | 1.51e-04 | 122 |
GO:00302167 | Esophagus | ESCC | keratinocyte differentiation | 86/8552 | 139/18723 | 8.53e-05 | 6.19e-04 | 86 |
GO:00451035 | Esophagus | ESCC | intermediate filament-based process | 32/8552 | 52/18723 | 1.55e-02 | 4.97e-02 | 32 |
GO:00435887 | Oral cavity | OSCC | skin development | 143/7305 | 263/18723 | 2.77e-07 | 4.27e-06 | 143 |
GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
GO:00302166 | Oral cavity | OSCC | keratinocyte differentiation | 81/7305 | 139/18723 | 3.16e-06 | 3.81e-05 | 81 |
GO:00099139 | Oral cavity | OSCC | epidermal cell differentiation | 109/7305 | 202/18723 | 1.08e-05 | 1.14e-04 | 109 |
GO:00451044 | Oral cavity | OSCC | intermediate filament cytoskeleton organization | 31/7305 | 51/18723 | 1.34e-03 | 6.62e-03 | 31 |
GO:00451034 | Oral cavity | OSCC | intermediate filament-based process | 31/7305 | 52/18723 | 2.08e-03 | 9.59e-03 | 31 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TCHH | SNV | Missense_Mutation | novel | c.479N>A | p.Arg160Gln | p.R160Q | Q07283 | protein_coding | tolerated_low_confidence(0.05) | benign(0.261) | TCGA-A1-A0SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TCHH | SNV | Missense_Mutation | c.4285N>A | p.Asp1429Asn | p.D1429N | Q07283 | protein_coding | deleterious_low_confidence(0.01) | benign(0.11) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TCHH | SNV | Missense_Mutation | novel | c.3321N>C | p.Glu1107Asp | p.E1107D | Q07283 | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-A1-A0SN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD |
TCHH | SNV | Missense_Mutation | rs751135364 | c.5143N>A | p.Gln1715Lys | p.Q1715K | Q07283 | protein_coding | deleterious_low_confidence(0.01) | benign(0.071) | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TCHH | SNV | Missense_Mutation | c.553N>C | p.Glu185Gln | p.E185Q | Q07283 | protein_coding | deleterious_low_confidence(0.01) | benign(0.035) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
TCHH | SNV | Missense_Mutation | c.3385N>A | p.Glu1129Lys | p.E1129K | Q07283 | protein_coding | deleterious_low_confidence(0.01) | benign(0.019) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
TCHH | SNV | Missense_Mutation | c.202N>T | p.Arg68Cys | p.R68C | Q07283 | protein_coding | tolerated_low_confidence(0.07) | probably_damaging(0.961) | TCGA-A2-A0SW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD | |
TCHH | SNV | Missense_Mutation | rs751135364 | c.5143N>A | p.Gln1715Lys | p.Q1715K | Q07283 | protein_coding | deleterious_low_confidence(0.01) | benign(0.071) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD |
TCHH | SNV | Missense_Mutation | rs751135364 | c.5143C>A | p.Gln1715Lys | p.Q1715K | Q07283 | protein_coding | deleterious_low_confidence(0.01) | benign(0.071) | TCGA-A2-A0YE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
TCHH | SNV | Missense_Mutation | c.3403G>A | p.Glu1135Lys | p.E1135K | Q07283 | protein_coding | tolerated_low_confidence(0.14) | benign(0.043) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |